Although BRQ lacked robust single-agent efficacy in tumor models, it did reduce the prevalence of spontaneous lung metastases and showed enhanced efficacy when combined with antibodies targeting the programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoints. The gene discussed is PDCD1; the disease is neoplasm.